Mirtazapin Orion (Mirtazapine)

Mirtazapine acts on noradrenergic and serotonergic pathways to treat depressive disorders.

• Major depressive disorder: reduces core depressive symptoms such as low mood, loss of interest, and low energy, leading to improved functional capacity in adult patients.
• Depressive episodes with insomnia: enhances sleep continuity, reduces nighttime awakenings, and contributes to better daytime alertness.
• Depression with anxiety features: alleviates concurrent anxiety, tension, and irritability, supporting overall emotional stability.

• Mirtazapine blocks central presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A. This combined action enhances serotonergic and noradrenergic neurotransmission, leading to mood elevation and improved sleep architecture. The drug’s antagonism at histamine H1 receptors also contributes to its sedative properties, while its lack of significant cholinergic activity reduces anticholinergic side effects. Overall, this pharmacological profile differentiates it from typical SSRIs and SNRIs.

Mirtazapine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Sedation or drowsiness
• Increased appetite leading to weight gain
• Dry mouth
• Constipation

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Suicidal thoughts or behavior, especially early in treatment
• Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing mirtazapine, clinicians should consider several safety precautions to minimize risk.

• Assess hepatic function: adjust use in patients with severe liver impairment.
• Monitor body weight: significant weight gain may occur during therapy.
• Screen for suicidal ideation: heightened risk during initial weeks of treatment.
• Use caution in elderly patients: increased fall risk due to sedation and orthostatic hypotension.
• Avoid abrupt discontinuation: tapering reduces risk of withdrawal symptoms.
• Store at ambient temperature: keep in original packaging, protect from moisture.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis or serotonin syndrome.
• Other central nervous system depressants (e.g., alcohol, benzodiazepines): may enhance sedation and respiratory depression.
• Serotonergic agents (e.g., tramadol, linezolid): increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase drug exposure.
• Antihypertensive medications: additive hypotensive effect may require dose adjustment.